Scarica l'app Stockscreener
1.14
2.56%
-0.03
Dopo l'orario di chiusura:
1.14
Precedente Chiudi:
$1.17
Aprire:
$1.17
Volume 24 ore:
112.65K
Relative Volume:
0.25
Capitalizzazione di mercato:
$34.06M
Reddito:
-
Utile/perdita netta:
$-64.73M
Rapporto P/E:
-0.4043
EPS:
-2.82
Flusso di cassa netto:
$-53.29M
1 W Prestazione:
-8.80%
1M Prestazione:
-17.39%
6M Prestazione:
-55.29%
1 anno Prestazione:
-94.09%
Intervallo 1D:
$1.12
$1.19
Intervallo di 1 settimana:
$1.12
$1.27
Portata 52W:
$0.87
$21.40
An 2 Therapeutics Inc Stock (ANTX) Company Profile
Nome
An 2 Therapeutics Inc
Settore
Industria
Telefono
(650) 331-9090
Indirizzo
1800 EL CAMINO REAL, SUITE D, MENLO PARK
Confronta ANTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANTX
An 2 Therapeutics Inc
|
1.14 | 34.06M | 0 | -64.73M | -53.29M | -2.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
An 2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-09 | Downgrade | Evercore ISI | In-line → Underperform |
| 2024-08-09 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-07-03 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-04-02 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2024-02-13 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-02-12 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-12 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-02-12 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-01-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
Mostra tutto
An 2 Therapeutics Inc Borsa (ANTX) Ultime notizie
Tectonic Therapeutic Announces Positive Interim Data from - GlobeNewswire
CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of - GlobeNewswire
Major Setback: CARGO's Cancer Treatment Shows Alarming Safety Issues, Forces Company Restructure - StockTitan
Is Summit Therapeutics Inc. (SMMT) the Unstoppable Stock to Buy in 2025? - Yahoo Finance
Allogene Therapeutics Activates First Clinical Sites for Pivotal Phase 2 Trial of Cema-Cel - CRISPR Medicine News
APLT Lead Plaintiff Deadline ApproachingContact Robbins LLP for Information About the Pending Class Action Against Applied Therapeutics, Inc. - The Malaysian Reserve
Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy - Yahoo Finance
Sarepta Therapeutics Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYS - Yahoo Finance
Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar - Yahoo Finance
Lisata Therapeutics unveils encouraging preliminary data from Phase 2 pancreatic cancer trial - Proactive Investors USA
Coeptis Therapeutics Regains Compliance with Nasdaq Listing Rule 5550(a)(2) - PR Newswire
Xilio Therapeutics Announces Initial Phase 2 Data for - GlobeNewswire
Applied Therapeutics, Inc. (APLT) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest Up 8.2% in December - Defense World
Short Interest in Structure Therapeutics Inc. (NASDAQ:GPCR) Rises By 5.8% - MarketBeat
Maze Therapeutics Inc. (MAZE): Phase 2 Biopharma Targeting Kidney Disease Files for IPO. - Smartkarma
Keros Therapeutics Announces Additional Update on the Phase 2 TROPOS Trial - The Manila Times
Here’s Why Cidara Therapeutics, Inc. (CDTX) Is Skyrocketing - Yahoo Finance
Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics - GlobeNewswire
Rapport Therapeutics Announces Positive Results from PET and MAD-2 Trials for RAP-219On January 9, 2025, Rapport Therapeutics, Inc. (NASDAQ: RAPP) disclosed the outcomes from its positron emission tomography (PET) trial and the second multiple as - Defense World
Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) - Business Wire
Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension - Marketscreener.com
Mineralys Therapeutics Advances Lorundrostat to Phase 2 Trials - TipRanks
Mineralys Therapeutics Announces Phase 2 Clinical Trial of - GlobeNewswire
Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity - PR Newswire
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) - Yahoo Finance
Denali Therapeutics Announces Topline Results for Regimen G - GlobeNewswire
Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation - Yahoo Finance
Analysts Expect Breakeven For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Before Long - Yahoo Finance
Exicure (XCUR) to Acquire GPCR USA, Gains Phase 2 Cancer Drug Pipeline with $2B Market Potential - StockTitan
Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD - The Manila Times
Why Did Summit Therapeutics Inc. (SMMT) Jump Yesterday? - Yahoo Finance
Grace Therapeutics And 2 Other US Penny Stocks Worth Watching - Simply Wall St
Investor Notice: Robbins LLP Informs Stockholders of the Class Action Lawsuit Filed Against Applied Therapeutics, Inc. - The Malaysian Reserve
Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI - GlobeNewswire
Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies - GlobeNewswire
Cognition Therapeutics, Inc. Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies - Marketscreener.com
Actuate Therapeutics Announces Positive Interim Phase 2 - GlobeNewswire
Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy - GlobeNewswire
Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 - GlobeNewswire
Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker) - Business Wire
Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease - Business Wire
Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks - Seeking Alpha
Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024 - Business Wire
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Brea - PR Newswire
Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial - GlobeNewswire
Atossa Therapeutics Announces Full Results from Phase 2 - GlobeNewswire
Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium - Yahoo Finance
Beam Therapeutics Announces New Data from BEACON Phase 1/2 - GlobeNewswire
Protara Therapeutics, Inc. Announces Positive Results from the Ongoing Phase 2 Advanced Advanced-2 Trial of TARA-002 in Patients with NMIBC - Marketscreener.com
Nuvig Therapeutics Announces $161 Million Series B Financing and Progression to Phase 2 Development with Novel, Second-Generation Immunomodulator - Business Wire
An 2 Therapeutics Inc Azioni (ANTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):